



Six-month interim report (Q2) 2010

August 23, 2010

(unaudited)

Performance for the period

(Comparative figures for the same period of last year are shown in brackets/sales growth is measured in local currencies)

- The positive trend in sales continued during Q2, during which vaccine sales grew by 12%
- Total revenue for H1 was DKK 1,035 million (927) with 11% growth in vaccine sales
- Operating profit before depreciation and amortisation (EBITDA) for H1 increased to DKK 152 million (110)
- Operating profit (EBIT) for H1 increased by 52% to DKK 108 million (71)
- Profit for H1 was DKK 83 million (54)

During the first six months of the year ALK experienced satisfactory growth in both sales and earnings, which was broadly based on products and markets. The positive progress in ALK's business during the past quarters thus continued.

With effect from 1 July 2010, ALK has acquired the Dutch company Artu from Fornix Biosciences. The company is now being now integrated into ALK's Dutch subsidiary.

ALK has also completed the acquisition of a small American company, Nelco Laboratories, with effect from 1 August 2010.

Adjusting expectations for 2010 upwards

For the 2010 financial year and including the impact of acquisitions undertaken, ALK now anticipates growth of 9-12% in the sale of allergy vaccines, measured in local currencies, as against the previous 5-8%. ALK now expects a gain in operating profit (EBITDA and EBIT) of 10-15% as against a smaller gain previously. The consequences of the healthcare reform carried out in Germany have been factored into this outlook.

Hørsholm, 23 August 2010

ALK-Abelló A/S

Contact:

Jens Bager, President and CEO, tel. +45 4574 7576.

ALK holds a conference call for analysts and investors today at 11.00 a.m. (CET) at which Jens Bager, President and CEO, will present the results. Participants in the conference call are kindly requested to call in before 10.55 a.m. (CET). Danish participants should call in on tel. +45 7026 5040 or +45 3271 4767 and international participants should call in on tel. +44 208 817 9301. The conference call will also be webcast on our website: www.alk-abello.com, where the related presentation will be available shortly before the conference call begins.